Pipeline And Predictive Toxicology Will Unlock Future Success

Key Takeaways

• Advancements in clinical programs and strategic partnerships position the company for long-term revenue growth and improved earnings visibility.
  
• Increasing demand and improvements in AI-driven software drive higher market penetration, recurring SaaS revenues, and stronger operating margins.
  
• Reliance on existing customers, pressure on margins from investment shifts, dependency on volatile milestone revenues, and market headwinds threaten sustained growth and profitability.

Catalysts

Develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications.

• Strong pipeline advancement and early clinical success, such as positive Phase I data for SGR-1505, positions the company to secure additional milestone payments, royalties, and out-licensing deals, creating potential for substantial long-term revenue growth and more predictable future cash flows.
  
• Increasing adoption of predictive toxicology and other AI-driven modules, as supported by FDA initiatives to modernize drug discovery and reduce reliance on animal models, is likely to deepen demand for Schrödinger's software, expanding the customer base and driving higher SaaS recurring revenues.
  
• Ongoing improvements in the performance, usability, and accessibility of Schrödinger's proprietary software-including new streamlined workflows and expansion to non-specialist users-support greater market penetration and higher renewal/expansion rates, which can enhance overall revenue growth and margin expansion.
  
• Expansion of large-scale strategic partnerships and collaborations (e.g., with Novartis, Lilly, and Otsuka), combined with consistent 100% retention among largest customers and robust renewal discussions, increase near
• and long-term earnings visibility and reduce churn risk, stabilizing future earnings and free cash flow.
  
• Effective cost management and a reduction in operating expenses, alongside a robust cash position, are likely to support improved operating margins and a shorter path to profitability as investments in high-impact R&D initiatives transition to revenue-generating products.

Schrödinger Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Schrödinger's revenue will grow by 11.2% annually over the next 3 years.
• Analysts are not forecasting that Schrödinger will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Schrödinger's profit margin will increase from -40.4% to the average US Healthcare Services industry of 6.0% in 3 years.
• If Schrödinger's profit margin were to converge on the industry average, you could expect earnings to reach $21.2 million (and earnings per share of $0.28) by about April 2029, up from -$103.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $83.8 million in earnings, and the most bearish expecting $-137.8 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 97.1x on those 2029 earnings, up from -8.6x today. This future PE is greater than the current PE for the US Healthcare Services industry at 31.7x.
• Analysts expect the number of shares outstanding to grow by 0.61% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.56%, as per the Simply Wall St company report.

Risks

• Schrödinger's software revenue growth is primarily driven by increased utilization within existing accounts rather than expanding its customer base, with persistent biotech sector challenges limiting new client acquisition and constraining long-term revenue growth potential.
  
• The significant reduction in software gross margin from 80% to 68% year-over-year reflects a shift in revenue mix and increased investment in the predictive toxicology initiative, and this trend is expected to continue for up to two years, potentially putting sustained pressure on net margins and overall profitability.
  
• Heavy reliance on milestone and royalty revenue from collaborations and pipeline partnerships introduces long-term revenue volatility and uncertainty, compounded by lengthy drug development timelines and a dependency on successful late-stage out-licensing to external partners.
  
• Ongoing macroeconomic pressures-including regulatory and tariff uncertainty, challenging capital markets, and increased drug pricing scrutiny-may dampen R&D spend among both pharma and especially biotech clients, negatively impacting demand for Schrödinger's products and threatening future earnings growth.
  
• The need for headcount reductions and $30 million expense cuts despite a strong balance sheet and growing revenues signals ongoing pressures on cost management and efficiency, which, if persistent, could delay scalability and limit the company's ability to realize sustained operating margin improvements.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $21.38 for Schrödinger based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $13.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $351.5 million, earnings will come to $21.2 million, and it would be trading on a PE ratio of 97.1x, assuming you use a discount rate of 8.6%.
• Given the current share price of $12.06, the analyst price target of $21.38 is 43.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.